Table 2.
Univariate analysis for 5-year bDFS.
| 5-year bDFS % (95% CI) | p value* | |
|---|---|---|
| PSA cut-off | ||
| <0.2 ng/ml | 81% (95% CI 73–87) | 0.06 |
| ≥0.2 ng/ml | 68% (95% CI 56–77) | |
| <0.02 ng/ml | 86% (95% CI 63–95) | 0.03 |
| ≥0.02 ng/ml | 73% (95% CI 66–79) | |
| Risk class17 | ||
| Low risk | 86% (95% CI 76–92) | 0.01 |
| Intermediate risk | 75% (95% CI 61–84) | |
| High risk | 63% (95% CI 48–75) | |
| Pathological nodal status | ||
| pN0 | 71% (95% CI 61–78) | 0.003 |
| pN1 | 49% (95% CI 22–72) | |
| pNx | 89% (95% CI 80–94) | |
| Pathological Gleason score | ||
| 4–6 (61 pts, 22%) | 92% (95% CI 78–98) | 0.0006 |
| 7 (125 pts, 44%) | 81% (95% CI 72–88) | |
| 8–10 (96 pts, 34%) | 59% (95% CI 45–71) | |
| Surgical margins status | ||
| Positive | 72% (95% CI 64–79) | 0.10 |
| Negative | 85% (95% CI 74–92) | |
| Adjuvant hormonal therapy | ||
| Yes | 67% (95% CI 56–76) | 0.02 |
| No | 84% (95% CI 75–89) | |
*
Log-rank test.